- Conditions
- Healthy Volunteers
- Interventions
- Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC)
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 887
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acne Vulgaris
- Interventions
- drospirenone and ethinyl estradiol, Placebo tablet
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Ribociclib, Fulvestrant, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 10
- States / cities
- Anaheim, California • Palo Alto, California • Jacksonville, Florida + 7 more
- Conditions
- Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- 3 mg DRSP/20 μg EE
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 16 Years to 35 Years · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Breast Cancer, Hot Flashes, Menopausal Symptoms
- Interventions
- conjugated estrogens, medroxyprogesterone
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more
- Conditions
- Contraception
- Interventions
- NES/EE CVR
- Combination Product
- Lead sponsor
- Population Council
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 1,135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2014
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
- Conditions
- Contraception
- Interventions
- Ulipristal Acetate, Combined Oral Contraceptive Pill
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Transgender, Gender Identity, Vascular Stiffness, Vascular Inflammation, Insulin Sensitivity, Blood Pressure, Lipid Disorder, Appetitive Behavior
- Interventions
- No intervention
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Healthy Adults
- Interventions
- PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Breast Cancer
- Interventions
- LEE011, BYL719, fulvestrant, BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
- Interventions
- Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane
- Drug
- Lead sponsor
- Olema Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 47
- States / cities
- Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more
- Conditions
- Breast Neoplasms
- Interventions
- Abemaciclib, Fulvestrant, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 43
- States / cities
- Jonesboro, Arkansas • Springdale, Arkansas • La Jolla, California + 36 more
- Conditions
- Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
- Interventions
- Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2035
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Ovulation
- Interventions
- NES/E2 gel
- Drug
- Lead sponsor
- Population Council
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Bariatric Surgery Candidate, Contraception
- Interventions
- ethinyl estradiol-levonorgestrel
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sexual Dysfunction, Physiological
- Interventions
- Testosterone Cream, Estring
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Interventions
- Neratinib, Fulvestrant, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
- Conditions
- Healthy
- Interventions
- Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Fear, Fear; Examination, Phobic
- Interventions
- Estradiol 2Mg Tablet, Estradiol 4Mg Tablet, Placebo Pills
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Perimenopausal Depression, Post Menopausal, Healthy, Depression
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Vaginal Atrophy
- Interventions
- Bazedoxifene/Conjugated Estrogen
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
- Conditions
- Primary Ovarian Insufficiency
- Interventions
- Hormone Replacement Therapy, Combined Oral Contraceptives
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 14 Years to 45 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abemaciclib, Fulvestrant, Standard Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 55
- States / cities
- Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more